&nbsp;

Drugs Used:

bortezomib (PDRP prior authorization),

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Pre-SCT

ODB Limited Use

lenalidomide - Induction therapy for transplant eligible, newly diagnosed multiple myeloma, according to clinical criteria

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Blinatumomab - Front-line Consolidation for B-cell Precursor Acute Lymphoblastic Leukemia

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Drug

acalabrutinib

Other Name(s): Calquence®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 1969

Drug

abemaciclib

Other Name(s): Verzenio®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Oct 2025

Drug

anastrozole

Other Name(s): Arimidex®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 1969

Regimen

ACAL

Cancer Type:

Hematologic

Intent: Palliative

Drugs Used:

acalabrutinib (Unfunded)

Quick Link(s):

Regimen Monograph

Regimen

ACAL

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria

Drugs Used:

acalabrutinib

Quick Link(s):

Regimen Monograph

Regimen

ACALBEND+RITU; ACAL+RITU(MNT)

Cancer Type:

Hematologic

Intent: Palliative

Funding:

New Drug Funding Program

Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Exceptional Access Program

acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

BEND+POLA+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

New Drug Funding Program

Polatuzumab Vedotin with Bendamustine and Rituximab (Biosimilar) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

Drugs Used: